Envestnet Asset Management
CHRS icon

Envestnet Asset Management’s Coherus Oncology CHRS Stock Holding History

Envestnet Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$197K Sell
140,870
-11,324
-7% -$18.5K ﹤0.01% 4651
2026
Q1 		$257K Buy
+152,194
New +$270K ﹤0.01% 4372
2024
Q1 		– Sell
-11,892
Closed -$39.6K – 4198
2023
Q4 		$39.6K Sell
11,892
-10,258
-46% -$27.5K ﹤0.01% 3995
2023
Q3 		$82.8K Buy
22,150
+5,857
+36% +$27.1K ﹤0.01% 3895
2023
Q2 		$69.6K Sell
16,293
-840
-5% -$4.96K ﹤0.01% 3856
2023
Q1 		$117K Buy
17,133
+1,154
+7% +$8.96K ﹤0.01% 3775
2022
Q4 		$127K Sell
15,979
-8,212
-34% -$63.2K ﹤0.01% 3769
2022
Q3 		$232K Buy
24,191
+6,345
+36% +$64.2K ﹤0.01% 3506
2022
Q2 		$129K Sell
17,846
-1,122
-6% -$9.76K ﹤0.01% 3721
2022
Q1 		$245K Sell
18,968
-7,221
-28% -$91.8K ﹤0.01% 3562
2021
Q4 		$418K Buy
26,189
+3,136
+14% +$54.8K ﹤0.01% 3186
2021
Q3 		$370K Buy
23,053
+2,346
+11% +$34.4K ﹤0.01% 3162
2021
Q2 		$286K Buy
20,707
+257
+1% +$3.64K ﹤0.01% 3314
2021
Q1 		$299K Sell
20,450
-173
-0.8% -$2.94K ﹤0.01% 3133
2020
Q4 		$358K Buy
20,623
+6,884
+50% +$123K ﹤0.01% 2832
2020
Q3 		$252K Sell
13,739
-496
-3% -$9.23K ﹤0.01% 2808
2020
Q2 		$254K Sell
14,235
-35,742
-72% -$605K ﹤0.01% 2764
2020
Q1 		$811K Buy
49,977
+4,798
+11% +$88.6K ﹤0.01% 1943
2019
Q4 		$813K Buy
45,179
+2,476
+6% +$45.7K ﹤0.01% 2159
2019
Q3 		$865K Buy
+42,703
New +$853K ﹤0.01% 2043
2018
Q3 		– Sell
-1,261
Closed -$18K – 1469
2018
Q2 		$18K Buy
1,261
+209
+20% +$2.99K ﹤0.01% 2442
2018
Q1 		$12K Buy
1,052
+516
+96% +$5.64K ﹤0.01% 2461
2017
Q4 		$5K Buy
+536
New +$5.74K ﹤0.01% 2735

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Envestnet Asset Management's CHRS Position: Q2 2026 in Review

Envestnet Asset Management reduced its Coherus Oncology (CHRS) stake by 7.4% in Q2 2026, selling an estimated $18.5K and leaving 140,870 shares worth $197K. The position accounts for ﹤0.01% of the portfolio, ranked #4651.

Envestnet Asset Management first reported a position in CHRS in Q4 2017 and has held it in 23 quarters since. The position peaked at $865K in Q3 2019. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Envestnet Asset Management held 140,870 shares of Coherus Oncology worth $197K as of Q2 2026.
  • Envestnet Asset Management sold 11,324 Coherus Oncology shares in Q2 2026, an estimated $18.5K.
  • Coherus Oncology made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #4651 holding.
  • Envestnet Asset Management first reported a position in Coherus Oncology in Q4 2017 and has held it in 23 quarters since.
  • Envestnet Asset Management's Coherus Oncology position peaked at $865K in Q3 2019.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.